5-year KEYNOTE-826 data show sustained survival benefit in cervical cancer

An exploratory 5-year analysis of the phase 3 KEYNOTE-826 trial (median follow-up 59.1 months) evaluated pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in 617 patients with previously untreated persistent, recurrent, or metastatic cervical cancer. The trial reported sustained overall survival benefit with pembrolizumab versus placebo in both the PD-L1 combined positive score of at least 1 group (HR, 0.62) and the intention-to-treat population (HR, 0.64), with a similarly maintained progression-free survival advantage. The authors state no new safety signals were observed and no additional treatment-related deaths occurred since the final analysis, and they characterize the findings as confirming durability of benefit for this combination as a first-line option.

Most relevant for: Patients with previously untreated persistent, recurrent, or metastatic cervical cancer

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.